Luna, A.
Pérez-Lamas, L.
Boque, C.
Giraldo, P.
Xicoy, B.
Ruiz Nuño, C.
Vega, M. Moreno
Alvarez-Larrán, A.
Salamanca, A.
García-Noblejas, A.
Vall-Llovera, F.
Villalon, L.
De las Heras, N.
Ramila, E.
Pérez-Encinas, M.
Cuevas, B.
Perez-Lopez, R.
Sanchez-Guijo, F.
Jiménez-Velasco, A.
Lakhwani, S.
Casado, L. Felipe
Rosell, A.
Escola, A.
Fernández, M. J.
Garcia-Hernandez, C.
Cervero, C.
Mora, E.
Sagüés, M.
Suarez-Varela, S.
Vélez, P.
Carrascosa Mastell, P.
Bitaube, R. F.
Serrano, L.
Cortes, M.
Vera Goñi, J.A
Steegmann, J. L.
de Soria, V. Gomez Garcia
Alonso-Dominguez, J. M.
Araujo, M. Colorado
Coll, A. Paz
Hernandez-Boluda, J.C
García-Gutiérrez, V.
Article History
Received: 19 April 2022
Accepted: 22 July 2022
First Online: 23 August 2022
Declarations
:
: •L. Pérez-Lamas: Novartis: sponsored travel.•V. García-Gutiérrez: Novartis: Speaker Honoraria, advisory committees. BMS, Incyte, Pfizer, CTA consultancy, honoraria, and research funding.•F. Sanchez Guijo, Novartis, Celgene, Incyte, Pfizer, Takeda, Roche, Gilead, Amgen Consultancy, and horonaria.•JM. Alonso-Dominguez: research funding from Incyte, Celgene, Pfizer, Astellas. BMS: Speaker Honoraria, advisory committees; Pfizer: Speaker Honoraria, advisory committees. Incyte: Advisory committees.•S. Lakhwani: Novartis: Speaker honoraria, advisory committees; BMS: Speaker honoraria.